Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
about
Morphologic and Functional Imaging of Non-Colorectal Liver MetastasesClinical applications of Gallium-68Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumoursInsights into bombesin receptors and ligands: Highlighting recent advancesImaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentLoss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseMedical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)Neuroendocrine tumours of the head and neck: anatomical, functional and molecular imaging and contemporary management.Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.Somatostatin analogues for receptor targeted photodynamic therapyNeuroendocrine tumors of the gastrointestinal tract: Case reports and literature review.An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.Therapy for metastatic pancreatic neuroendocrine tumors.Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.64Cu-labeled somatostatin analogues conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studiesLigand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.Feasibility of imaging esophageal cancer with labeled somatostatin analogueSomatostatin receptor based imaging and radionuclide therapy.Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.Stroma targeting nuclear imaging and radiopharmaceuticals.A Strong Stomach for Somatostatin.The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.Somatostatin receptor staining in FFPE sections using a ligand derivative dye as an alternative to immunostaining.Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphyRadiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.Peptide receptor targeting in cancer: the somatostatin paradigm.Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptorsTherapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesBone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementDoes PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrEvaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.
P2860
Q26765003-1367805A-12F2-4271-845B-3251B5E2E81BQ26849276-2EB7369A-6574-4E4C-A0BA-48AA3877A6C2Q28071483-2570321A-8B22-4200-9041-84AE0B051E4FQ28081153-B17E8810-5621-4EA0-A63A-BE5EDB8CC70BQ28083433-884725CE-6310-40C6-8FDA-DE1E44261828Q28540624-113B776C-1E39-4D6C-8768-961BBD41B673Q28732809-B44D18D2-7E7A-4304-B8E3-45A7033CAA11Q30412504-C91F026C-837B-4FC8-A06C-756DB4885DD6Q30884794-627A72BF-DA56-44C5-B549-DAEF72AAEC6BQ33397018-5A878115-DA0D-40EC-B80C-8DCB549374F8Q34027669-55FF08CD-93EC-4DC0-927F-0A409DEB63B5Q34049125-1D5EC1F7-9357-434E-A330-32F1A36007AEQ34093032-B399E575-B3DF-407A-93ED-3D6CEE8A6D5CQ34357869-DDA217C0-0BA0-4537-A974-BAF38D47D811Q34477028-8A40B55D-79FC-479C-9702-35D4C4D57349Q34665668-9DB910A8-889C-45A2-9E53-D513428C9A52Q35001258-BD1EFFD2-404F-4D08-9BE4-4B70F103A811Q35049485-FE0A3262-8348-4A0A-AF3D-9A76C9D80BB3Q35296661-39B5FB80-6A85-4494-B0E7-33003A41194CQ35951881-7BDA8A5F-5603-46D3-8BDA-5D8D7E360459Q35999552-CD7C3D0E-9B3E-4727-ACB6-17E6CD147E77Q35999606-1DFD2E2F-5E7A-4F45-94D2-CF28E7300A01Q36164361-C6198705-0A1D-4C38-BAB8-09F0D40E5CAAQ36208460-297AA239-15D4-4263-BEA2-74ECA29AEF7EQ36275836-A943A10B-F4CC-4785-947A-486E15AD49B6Q36300599-9619D1ED-250E-4034-8208-7AE35F1CCAAAQ36423806-BB73F8CE-9D83-4878-AA81-90B126EFA5F1Q36495946-D1EC6940-5503-478C-9823-02DB7877A840Q36638046-DB156863-2E13-4803-A018-BD22A2368572Q36661451-D909ED01-15A3-4989-8D84-93858553918BQ36755905-17857B29-5401-4A8B-BCC1-1EE7FEEE2CC8Q36849357-1F27053A-6879-4E0B-ABA3-33551C67700CQ37122608-67BA3704-A752-4AF0-9048-F8805DD3165EQ37125550-4163F044-B071-4FB2-99B1-19270BD0EE9FQ37201458-B08DF90C-AE6B-408C-967C-0186B5F25752Q37302087-94AE4E78-CDAC-4E2B-81A1-BA62ED249CBAQ37425156-B7A9D56F-B6F9-454D-A903-99EAFFA781F5Q37515861-210D33A4-19F4-4F09-9CE8-AAEAFF78357CQ37558860-75DAC5D9-ABE0-4064-B0A2-0F9C2A738965Q37731335-6B55CAFB-EA37-4FC2-ACA2-5B23E881A84B
P2860
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Somatostatin-receptor-based im ...... creatic neuroendocrine tumors.
@en
Somatostatin-receptor-based im ...... creatic neuroendocrine tumors.
@nl
type
label
Somatostatin-receptor-based im ...... creatic neuroendocrine tumors.
@en
Somatostatin-receptor-based im ...... creatic neuroendocrine tumors.
@nl
prefLabel
Somatostatin-receptor-based im ...... creatic neuroendocrine tumors.
@en
Somatostatin-receptor-based im ...... creatic neuroendocrine tumors.
@nl
P2093
P356
P1476
Somatostatin-receptor-based im ...... creatic neuroendocrine tumors.
@en
P2093
Boen L Kam
Casper H J van Eijck
Dik J Kwekkeboom
Eric P Krenning
Jaap J M Teunissen
Marion de Jong
Martijn van Essen
Roelf Valkema
P304
P356
10.1677/ERC-09-0078
P577
2010-01-29T00:00:00Z